Total Pageviews

9/12/2011

Building Blog "The Shape of War"

ARCHITECTURAL CONJECTURE URBAN SPECULATION LANDSCAPE FUTURES BLDGBLOG ("BUILDING BLOG") IS WRITTEN BY GEOFF MANAUGH. THE OPINIONS EXPRESSED ON BLDGBLOG ARE MY OWN; THEY DO NOT REFLECT THE VIEWS OF MY EDITORS, EMPLOYERS, PUBLISHERS, FRIENDS, OR COLLEAGUES, WITH WHOM THIS BLOG IS NOT AFFILIATED.

"As Norfolk says in the BLDGBLOG interview, and which perhaps serves as a useful conceptual umbrella for the entire forthcoming evening:
All of the work that I’ve been doing over the last five years is about warfare and the way war makes the world we live in. War shapes and designs our society. The landscapes that I look at are created by warfare and conflict. This is particularly true in Europe. I went to the city of Cologne, for instance, and the city of Cologne was built by Charlemagne—but Cologne has the shape that it does today because of the abilities and non-abilities of a Lancaster Bomber. It comes from what a Lancaster can do and what a Lancaster can't do. What it cannot do is fly deep into Germany in the middle of the day and pinpoint-bomb a ball bearing factory. What it can do is fly to places that are quite near to England, that are five miles across, on a bend in the river, under moonlight, and then hit them with large amounts of H.E.. And if you do that, you end up with a city that looks like Cologne—the way the city's shaped.

So I started off in Afghanistan photographing literal battlefields—but I'm trying to stretch that idea of what a battlefield is. Because all the interesting money now—the new money, the exciting stuff—is about entirely new realms of warfare: inside cyberspace, inside parts of the electromagnetic spectrum. Eavesdropping, intelligence, satellite warfare, imaging—this is where all the exciting stuff is going to happen in twenty years' time. So I wanted to stretch that idea of what a battleground could be. What is a landscape—a surface, an environment, a space—created by warfare?"

1 comment:

  1. AstraZeneca announced the start of anti-cancer drug Vandetanib Phase III clinical study

    AstraZeneca in February 26, 2007 announced to take international cooperation, double-blind, parallel, and the way to start anti-tumor drug Vandetanib Phase III clinical studies, indications are used after failure of first-line anti-cancer drugs for non-small cell lung cancer (NSCLC ). The Phase III clinical study in the United States selected the 20 hospitals, while the other 19 countries to participate in a total of 508 patients involved in clinical research. Vandetanib orally once daily, with reference to drugs is another second-line drugs Alimta. Grouped into Vandetanib and Alimta Ng, or Alimta and placebo. The ultimate indicators include, progressive cancer free survival, overall survival, response rate to anticancer drugs and the reaction period, the role of the disease-related syndromes and security and so on. Vandetanib (trade name Zactima, ZD6474) is a compound similar to the targeting of drugs to combat targeted tumor growth and spread of multiple targets signaling pathways, such as epidermal growth factor receptor tyrosine kinase and vascular endothelial growth factor receptors. Vandetanib in Phase II clinical studies used alone or in combination with other drugs showed effect against non-small cell lung cancer.

    Medchemexpress Can provide the above product,its website:www.medchemexpress.com



    Tofacitinib
    Fludarabine phosphate
    Bardoxolone methyl
    NSC 74859
    Sorafenib Tosylate
    SB-590885
    Vemurafenib
    Dabrafenib
    GDC-0879
    PLX-4720

    ReplyDelete